Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 12 month open-label randomized parallel group study to investigate the influence of salmeterol/fluticasone (50/500 BD [two times a day]) either in fixed combination or separately via Diskus inhalers on the course of the disease and frequency of exacerbations in subjects with severe and very severe COPD [chronic obstructive pulmonary disease] (GOLD [Global Initiative for Chronic Obstructive Lung Disease] stage III+IV).

Next Previous
X
Search
Trial Profile

A 12 month open-label randomized parallel group study to investigate the influence of salmeterol/fluticasone (50/500 BD [two times a day]) either in fixed combination or separately via Diskus inhalers on the course of the disease and frequency of exacerbations in subjects with severe and very severe COPD [chronic obstructive pulmonary disease] (GOLD [Global Initiative for Chronic Obstructive Lung Disease] stage III+IV).

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluticasone propionate (Primary) ; Salmeterol (Primary) ; Salmeterol/fluticasone propionate (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms VIVESCO
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 23 Jun 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
    • 23 Jun 2010 Actual patient number (214) added as reported by ClinicalTrials.gov.
    • 23 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top